Home | Welcome to Contract Pharma   
Last Updated Friday, May 22 2015


Financial Report: PAREXEL

Published January 30, 2013

2Q Revenues: $483.1 million (+25%)

2Q Earnings: $21.3 million (+65%)

YTD Revenues: $945.7 million (+26%)

YTD Earnings: $36.4 million (+62%)

Comments: Clinical Research Services (CRS) revenue was $320.6 million in the quarter, up 29%. PAREXEL Consulting & Medical Communications Services (PCMS) revenues were $49.3 million, up 28%. Perceptive Informatics (PI) revenues were $101.4 million, up 12%. Newly-acquired Liquent, Inc. contributed $0.4 million to revenue in the quarter. Backlog at the end of December 2012 was approximately $4.5 billion, up 21%.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On